SCII Stem Cell Therapy International Corporation, featured news, full reports, and detailed SCII.OB charts.
Stem Cell Therapy International Corporation (SCII/SCII.OB) Wrap Up:
Stem Cell Therapy International, Inc., through its subsidiary, Stem Cell Therapy International Corp., engages in licensing of stem cell technology and the sale of stem cell products, as well as the provision of information, education, and referral services. It offers allo stem cell biological solutions that are used in the treatment of patients suffering from degenerative disorders of the human body, such as Alzheimer's Disease, Parkinson's Disease, ALS, leukemia, muscular dystrophy, multiple sclerosis, arthritis, spinal cord injuries, brain injury, stroke, heart disease, liver and retinal disease, and diabetes, as well as certain types of cancer. The companyâs stem cell biological solutions...
Stem Cell Therapy International Corporation (SCII:OTC Bulletin Board Market)
Snapshot of Stem Cell Therapy International Corporation (SCII)
|
OPEN
$0.15
|
PREVIOUS CLOSE
$0.14
|
|
|
DAY HIGH
$0.16
|
DAY LOW
$0.14
|
|
|
52 WEEK HIGH
09/16/09 - $0.50
|
52 WEEK LOW
11/17/08 - $0.0050
|
|
|
MARKET CAP
7.5M
|
AVERAGE VOLUME 3 mo
159.5K
|
|
|
DILUTED EPS TTM
--
|
SHARES OUTSTANDING
50.1M
|
|
|
SCII Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
SCII Details
Stem Cell Therapy International, Inc. operates in the field of regenerative medicine. The company focuses on the treatment of patients with stem cell transplantation therapy, as well as on the provision of biological solutions containing new lines of stem cell products. It offers allo (human) stem cell biological solutions for the treatment of patients suffering from degenerative disorders of the human body, such as Alzheimers, Parkinsons disease, ALS, leukemia, muscular dystrophy, multiple sclerosis, arthritis, spinal cord injuries, brain injury, stroke, heart disease, liver and retinal disease, and diabetes, as well as certain types of cancer. The company was founded in 2004 and is headquartered in Tampa, Florida.
SCII Top Compensated Officers
Executives, Board Directors
Key developments for Stem Cell Therapy International Corporation (SCII)
Stem Cell Therapy International Corporation plans to accelerate its growth through the strategic acquisitions of companies that will enhance or compliment its current service or product offerings. Each component of the Company plays an important roll in the strategy of driving long term, sustainable value for our shareholders.
Stem Cell Therapy International Corporation filed its 10-K on July 10, 2009 for the period ending March 31, 2009. In this report its auditor, Brimmer, Burek & Keelan LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
On 06/29/2009, Stem Cell Therapy International Corporation announced that they will be unable to file their next 10-K by the deadline required by the SEC.
SCII Competitors
| Company | Last | Change |
| Cord Blood America Inc | $0.0054 USD | +0.0003 |
| Cryo-Cell Intl Inc | $1.80 USD | -0.20 |
| International Stem Cell Corp | $0.62 USD | 0.00 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | SCII | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | -- | Not Meaningful |
| Price/Book | NM | Not Meaningful |
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | -- | Not Meaningful |
|
SCII |
||
SCII transactions
| Type Date |
Target |
|
Private Placement
November 3, 2009 |
-- |
More Recent News About Stem Cell Therapy International Corporation
-
Stem Cell Therapy International, Inc. and Histostem Korea Announce Providing Hematopoietic Stem Cell to Queen Mary Hospital, Hong Kong
Stem Cell Therapy International Inc. (OTCBB: SCII) and its soon to be subsidiary, Histostem Ltd. of South Korea ("Histostem"), announced that they...
Market Wire, 11/05/09 · More from publication